Advanced Enzyme Posts Strong Q3 Performance; Outlook Positive: ICICI Direct
A researcher tests enzymes in the enzyme research facility. (Photographer: Freya Ingrid Morales/Bloomberg)

Advanced Enzyme Posts Strong Q3 Performance; Outlook Positive: ICICI Direct


BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Advanced Enzyme Technologies Ltd.’s Q3 revenues grew 23.0% YoY to Rs 137.7 crore on the back of 34.9% YoY growth in human healthcare segment to Rs 108.9 crore.

Animal healthcare saw a decline of 29.5% YoY to Rs 10.5 crore whereas industrial processing segment grew 12.3% YoY to Rs 18.3 crore.

Ebitda margins expanded 97 basis points YoY to 48.2% with lower employee and other expenditure being partly offset by lower gross margins.

Hence, Ebitda grew 25.6% YoY to Rs 66.4 crore.

Profit after tax grew 28.2% YoY to Rs 43.1 crore in-line with operational performance.

Click on the attachment to read the full report:

ICICI Direct Advanced Enzymes Q3FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.